

Acta Crystallographica Section E

## Structure Reports

Online

ISSN 1600-5368

## 6,8-Dibromoquinoline

İsmail Çelik,<sup>a</sup> Mehmet Akkurt,<sup>b\*</sup> Osman Çakmak,<sup>c</sup> Salih Ökten<sup>c</sup> and Santiago García-Granda<sup>d</sup>

<sup>a</sup>Department of Physics, Faculty of Arts and Sciences, Cumhuriyet University, 58140 Sivas, Turkey, <sup>b</sup>Department of Physics, Faculty of Sciences, Erciyes University, 38039 Kayseri, Turkey, <sup>c</sup>Department of Chemistry, Faculty of Arts and Sciences, Gaziosmanpaşa University, 60240 Tokat, Turkey, and <sup>d</sup>Departamento Química Física y Analítica, Facultad de Química, Universidad Oviedo, C/ Julián Clavería, 8, 33006 Oviedo (Asturias), Spain

Correspondence e-mail: akkurt@erciyes.edu.tr


Received 20 October 2010; accepted 23 October 2010

Key indicators: single-crystal X-ray study;  $T = 297$  K; mean  $\sigma(\text{C}-\text{C}) = 0.010$  Å;  $R$  factor = 0.045;  $wR$  factor = 0.141; data-to-parameter ratio = 14.7.

The title molecule,  $\text{C}_9\text{H}_5\text{Br}_2\text{N}$ , is almost planar, with an r.m.s. deviation of 0.027 Å. The dihedral angle between the aromatic rings is  $1.5(3)^\circ$ . In the crystal,  $\pi-\pi$  stacking interactions are present between the pyridine and benzene rings of adjacent molecules [centroid-centroid distances =  $3.634(4)$  Å], and short  $\text{Br}\cdots\text{Br}$  contacts [ $3.4443(13)$  Å] occur.

## Related literature

For the biological and pharmacological activities of quinolines and their derivatives, see: Abadi *et al.* (2005); Blackie *et al.* (2007); Chen *et al.* (2006); Gómez *et al.* (2008); Gómez-Barrio *et al.* (2006); Kouznetsov *et al.* (2005, 2007); Lindley (1984); Metwally *et al.* (2006); Muscia *et al.* (2006); Musiol *et al.* (2007); Sissi & Palumbo (2003); Vangapandu *et al.* (2004); Vinsova *et al.* (2008); Vladímir *et al.* (2005); Zhao *et al.* (2005); Zhu *et al.* (2007); Şahin *et al.* (2008). For the synthesis, see: Ökten *et al.* (2010).



## Experimental

## Crystal data

$\text{C}_9\text{H}_5\text{Br}_2\text{N}$   
 $M_r = 286.94$   
 Monoclinic,  $P2_1/c$   
 $a = 7.3436(12)$  Å

$b = 9.8961(15)$  Å  
 $c = 13.0108(18)$  Å  
 $\beta = 109.589(17)^\circ$   
 $V = 890.8(3)$  Å<sup>3</sup>

$Z = 4$   
 Cu  $K\alpha$  radiation  
 $\mu = 11.04$  mm<sup>-1</sup>

$T = 297$  K  
 $0.12 \times 0.09 \times 0.02$  mm

## Data collection

Oxford Diffraction Xcalibur diffractometer with a Ruby Gemini CCD detector  
 Absorption correction: part of the refinement model ( $\Delta F$ )  
 (XABS2; Parkin *et al.*, 1995)  
 $T_{\min} = 0.052$ ,  $T_{\max} = 0.080$   
 1598 measured reflections  
 1598 independent reflections  
 1075 reflections with  $I > 2\sigma(I)$

## Refinement

$R[F^2 > 2\sigma(F^2)] = 0.045$   
 $wR(F^2) = 0.141$   
 $S = 1.02$   
 1598 reflections  
 109 parameters  
 H-atom parameters constrained  
 $\Delta\rho_{\max} = 0.68$  e Å<sup>-3</sup>  
 $\Delta\rho_{\min} = -0.56$  e Å<sup>-3</sup>

Data collection: *CrysAlis PRO* (Oxford Diffraction, 2009); cell refinement: *CrysAlis PRO*; data reduction: *CrysAlis PRO*; program(s) used to solve structure: *SIR97* (Altomare *et al.*, 1999); program(s) used to refine structure: *SHELXL97* (Sheldrick, 2008); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1999); software used to prepare material for publication: *WinGX* (Farrugia, 1997) and *PLATON* (Spek, 2009).

The authors thank the Cumhuriyet University Research Foundation (CUBAP grant No. 2009/ F-266) for financial support.

Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: HB5698).

## References

- Abadi, A., Hegazy, G. & El-Zaher, A. (2005). *Bioorg. Med. Chem.* **13**, 5759–5765.
- Altomare, A., Burla, M. C., Camalli, M., Cascarano, G. L., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). *J. Appl. Cryst.* **32**, 115–119.
- Blackie, M. A. L., Beagley, P., Croft, S. L., Kendrick, H., Moss, J. R. & Chibale, K. (2007). *Bioorg. Med. Chem.* **15**, 6510–6516.
- Chen, Y., Zhao, Y., Lu, C., Tzeng, C. & Wang, J. (2006). *Bioorg. Med. Chem.* **14**, 4373–4378.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Farrugia, L. J. (1999). *J. Appl. Cryst.* **32**, 837–838.
- Gómez, C. M. M., Kouznetsov, V. V., Sortino, M. A., Álvarez, S. L. & Zacchino, S. A. (2008). *Bioorg. Med. Chem.* **16**, 7908–7920.
- Gómez-Barrio, A., Montero-Pereira, D., Nogal-Ruiz, J. J., Escario, J. A., Muelas-Serrano, S., Kouznetsov, V. V., Vargas Mendez, L. Y., Urbina González, J. M. & Ochoa, C. (2006). *Acta Parasitol.* **51**, 73–78.
- Kouznetsov, V. V., Mendez, L. Y. V. & Gomez, C. M. M. (2005). *Curr. Org. Chem.* **9**, 141–146.
- Kouznetsov, V. V., Méndez, L. Y. V., Leal, S. M., Cruz, U. M., Coronado, C. A., Gómez, C. M. M., Bohórquez, A. R. R. & Rivero, P. E. (2007). *Lett. Drug. Des. Discov.* **4**, 293–296.
- Lindley, J. (1984). *Tetrahedron*, **40**, 1433–1456.
- Metwally, K. A., Abdel-Aziz, L. M., Lashine, E. M., Hussein, M. I. & Badawy, R. H. (2006). *Bioorg. Med. Chem.* **4**, 8675–8682.
- Muscia, G. C., Bollini, M., Carnevale, J. P., Bruno, A. M. & Asís, S. E. (2006). *Tetrahedron Lett.* **47**, 8811–8815.
- Musiol, R., Jampilek, J., Kralova, K., Richardson, D. R., Kalinowski, D., Podieszwa, B., Finster, J., Niedbala, H., Palka, A. & Polanski, J. (2007). *Bioorg. Med. Chem.* **15**, 1280–1288.
- Ökten, S., Çakmak, O. & Erenler, R. (2010). *Beilstein J. Chem.* In the press.
- Oxford Diffraction (2009). *CrysAlis PRO*. Oxford Diffraction Ltd, Yarnton, Oxfordshire, England.
- Parkin, S., Moezzi, B. & Hope, H. (1995). *J. Appl. Cryst.* **28**, 53–56.

- Şahin, A., Çakmak, O., Demirtaş, İ., Ökten, S. & Tutar, A. (2008). *Tetrahedron*, **64**, 10068–10074.
- Sheldrick, G. M. (2008). *Acta Cryst. A* **64**, 112–122.
- Sissi, C. & Palumbo, M. (2003). *Curr. Med. Chem. Anti-Canc. Agents*, **3**, 439–450.
- Spek, A. L. (2009). *Acta Cryst. D* **65**, 148–155.
- Vangapandu, S., Jain, M., Jain, R., Kaur, S. & Singh, P. P. (2004). *Bioorg. Med. Chem.* **12**, 2501–2508.
- Vinsova, J., Imramovsky, A., Jampilek, J., Monreal-Ferriz, J. & Dolezal, M. (2008). *Anti-Infective Agents Med. Chem.* **7**, 12–31.
- Vladimir, V., Kouznetsov, V. V., Vargas Méndez, L. Y. & Gómez, C. M. (2005). *Curr. Org. Chem.* **9**, 141–146.
- Zhao, Y. L., Chen, Y. L., Chang, F. S. & Tzeng, C. T. (2005). *Eur. J. Med. Chem.* **40**, 792–797.
- Zhu, X. Y., Mardenborough, L. G., Li, S., Khan, A., Zhang, W., Fan, P., Jacob, M., Khan, S., Walker, L. & Ablordeppey, S. Y. (2007). *Bioorg. Med. Chem.* **15**, 686–695.

**supplementary materials**

*Acta Cryst.* (2010). E66, o2997–o2998 [ doi:10.1107/S1600536810043242 ]

## 6,8-Dibromoquinoline

İ. Çelik, M. Akkurt, O. Çakmak, S. Ökten and S. García-Granda

### Comment

The quinoline skeleton is often used for designing of many synthetic compounds with diverse pharmacological and medicinal properties. Quinolines and their derivatives have shown to display a wide spectrum of biological activities such as antibacterial (Metwally *et al.*, 2006), antimycobacterial (Vinsova *et al.*, 2008; Vangapandu *et al.*, 2004), antineoplastic (Zhao *et al.*, 2005; Sissi & Palumbo, 2003; Musiol *et al.*, 2007; Zhu *et al.*, 2007), antiparasitical (Muscia *et al.*, 2006; Blackie *et al.*, 2007; Gómez *et al.*, 2008; Gómez-Barrio *et al.*, 2006; Kouznetsov *et al.*, 2005, 2007), and anti-inflammatory behavior (Chen *et al.*, 2006; Abadi *et al.*, 2005; Ökten *et al.*, 2010). Quinoline also constitutes a key structural component of numerous compounds with pharmacological activity, dyestuffs, materials with metal-halogen exchange, and agrochemical (Lindley, 1984) and couplings (Vladimir *et al.*, 2005). Bromoquinolines have been of interest for chemists as precursors for heterocyclic compounds due to important scaffolds in medicinal chemistry. It was developed a convenient synthetic methodology for 6,8-disubstituted quinoline derivatives and the values of 6,8-dibromoquinoline as precursors to the corresponding disubstituted quinolines were presented. New disubstituted quinoline derivatives were synthesized *via* substitution reaction by using 6,8-DiBrQ, converted to further substituted quinoline. That may serve for the synthesis of natural bioactive quinolines derivatives because there are many biological active 6 and 8- functionalized quinolines such as quinine, pentaquine, and plasmoguinine (Şahin *et al.*, 2008).

The molecular structure of the title compound (I) is shown in Fig. 1 with their respective labels. Bond lengths and angles in (I) are within normal ranges. In this structure, the quinoline motif (N1/C1–C9) is essentially planar with maximum deviations of 0.029 (7) Å for C3 and 0.031 (9) Å for C8. The Br1—C2—C3—C4 and Br2—C4—C5—C6 torsion angles are -179.0 (5) and 178.7 (5)°, respectively.

The crystal structure of (I) is stabilized by  $\pi$ – $\pi$  stacking interactions, along the *a* axis, between N1/C1/C6–C9 (centroid *Cg*1) and C1–C6 (centroid *Cg*2) rings, with a *Cg*1...*Cg*2 distance of 3.634 (4) Å, (Fig. 2).

### Experimental

6,8-DiBromo-1,2,3,4-tetrahydroquinoline was synthesized in proper literature (Ökten *et al.*, 2010). Then, DDQ (2 g, 6.88 mmol) was dissolved in freshly distilled and dried benzene (10 ml) under an argon atmosphere. To a solution of 6,8-diBrTHQ (1 g, 3.44 mmol) in benzene (30 ml) was added the solution of DDQ. The mixture was refluxed at 353 K for 36 h. Upon cooling, the dark green solidified mixture was filtered and the solvent was removed in vacuo. The residue was filtered from a short silica column (1/9, EtOAc/hexane, *R<sub>f</sub>* = 0.4). Recrystallization of the product from hexane–chloroform gave 6,8-diBrQ in a yield of 88% (868 mg) as colourless plates, m.p. 372–373 K. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 9.04 (dd, *J*<sub>23</sub> = 4.2 Hz, *J*<sub>24</sub> = 1.6 Hz, 1H, H<sub>2</sub>), 8.16 (d, *J*<sub>57</sub> = 2.4 Hz, 1H, H<sub>7</sub>), 8.09 (dd, *J*<sub>43</sub> = 8.3 Hz, *J*<sub>24</sub> = 1.6 Hz, 1H, H<sub>4</sub>), 7.96 (d, *J*<sub>57</sub> = 2.4 Hz, 1H, H<sub>5</sub>), 7.49 (dd, *J*<sub>32</sub> = 4.2 Hz, *J*<sub>34</sub> = 8.3 Hz, 1H, H<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 151.5, 144.1135.9, 135.7, 130.1, 129.7, 125.9, 122.7, 119.9; IR (KBr, cm<sup>-1</sup>) ν<sub>max</sub> 3026, 1638, 1617, 1587, 1545, 1467, 1443, 1347, 1306, 1183, 1084, 1030, 962,

## supplementary materials

857, 809, 779, 677, 593, 543, 501. GC-MS  $m/z$  289 (5,  $M^+$ ), 288 (50), 287 (10), 286 (98), 285 (10), 284 (42), 207 (30), 205 (31), 129 (5), 127 (10), 126 (100), 125 (14), 103 (15), 102 (14), 99 (37), 98 (33), 97 (20), 75 (19), 74 (22), 73 (42), 50 (18), 49 (52), 48 (14), 37 (7), 36 (7). Anal. Calcd for  $C_9H_5NBr_2$  (286.95): C 37.67, H 1.76%. Found: C 37.78, H 1.82%.

### Refinement

H atoms were included in geometric positions with C—H = 0.93 Å and refined by using a riding model [ $U_{iso}(H) = 1.2U_{eq}(C)$ ].

### Figures




Fig. 1. The title molecule with displacement ellipsoids for non-H atoms drawn at the 50% probability level.




Fig. 2. View of the packing of (I) down the  $a$  axis.

### 6,8-Dibromoquinoline

#### Crystal data

$C_9H_5Br_2N$

$M_r = 286.94$

Monoclinic,  $P2_1/c$

Hall symbol: -P 2ybc

$a = 7.3436$  (12) Å

$b = 9.8961$  (15) Å

$c = 13.0108$  (18) Å

$\beta = 109.589$  (17)°

$V = 890.8$  (3) Å<sup>3</sup>

$Z = 4$

$F(000) = 544$

$D_x = 2.140$  Mg m<sup>-3</sup>

Cu  $K\alpha$  radiation,  $\lambda = 1.54184$  Å

Cell parameters from 1247 reflections

$\theta = 3.6$ – $70.3$ °

$\mu = 11.04$  mm<sup>-1</sup>

$T = 297$  K

Plate, colourless

$0.12 \times 0.09 \times 0.02$  mm

*Data collection*

Oxford Diffraction Xcalibur diffractometer with a Ruby Gemini CCD detector	1598 independent reflections
Radiation source: Enhance (Cu) X-ray Source	1075 reflections with $I > 2\sigma(I)$
graphite	$R_{\text{int}} = 0.0000$
$\omega$ scans	$\theta_{\text{max}} = 70.5^\circ$ , $\theta_{\text{min}} = 5.8^\circ$
Absorption correction: part of the refinement model ( $\Delta F$ )	
[ <i>XABS2</i> (Parkin <i>et al.</i> , 1995); cubic fit to $\sin(\theta)/\lambda$ - 24 parameters]	$h = -8 \rightarrow 8$
$T_{\text{min}} = 0.052$ , $T_{\text{max}} = 0.080$	$k = 0 \rightarrow 11$
1598 measured reflections	$l = 0 \rightarrow 15$

*Refinement*

Refinement on $F^2$	Primary atom site location: structure-invariant direct methods
Least-squares matrix: full	Secondary atom site location: difference Fourier map
$R[F^2 > 2\sigma(F^2)] = 0.045$	Hydrogen site location: inferred from neighbouring sites
$wR(F^2) = 0.141$	H-atom parameters constrained
$S = 1.02$	$w = 1/[\sigma^2(F_o^2) + (0.0642P)^2]$
1598 reflections	where $P = (F_o^2 + 2F_c^2)/3$
109 parameters	$(\Delta/\sigma)_{\text{max}} < 0.001$
0 restraints	$\Delta\rho_{\text{max}} = 0.68 \text{ e } \text{\AA}^{-3}$
	$\Delta\rho_{\text{min}} = -0.56 \text{ e } \text{\AA}^{-3}$

*Special details*

**Geometry.** Bond distances, angles *etc.* have been calculated using the rounded fractional coordinates. All su's are estimated from the variances of the (full) variance-covariance matrix. The cell e.s.d.'s are taken into account in the estimation of distances, angles and torsion angles

**Refinement.** Refinement on  $F^2$  for ALL reflections except those flagged by the user for potential systematic errors. Weighted  $R$ -factors  $wR$  and all goodnesses of fit  $S$  are based on  $F^2$ , conventional  $R$ -factors  $R$  are based on  $F$ , with  $F$  set to zero for negative  $F^2$ . The observed criterion of  $F^2 > \sigma(F^2)$  is used only for calculating  $-R$ -factor-obs *etc.* and is not relevant to the choice of reflections for refinement.  $R$ -factors based on  $F^2$  are statistically about twice as large as those based on  $F$ , and  $R$ -factors based on ALL data will be even larger.

*Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters ( $\text{\AA}^2$ )*

	<i>x</i>	<i>y</i>	<i>z</i>	$U_{\text{iso}}^*/U_{\text{eq}}$
Br1	0.93324 (12)	0.16374 (8)	0.01474 (6)	0.0736 (3)
Br2	0.54665 (13)	0.49672 (10)	-0.34185 (6)	0.0832 (4)
N1	0.8781 (8)	0.4050 (6)	0.1454 (4)	0.0641 (19)
C1	0.8034 (8)	0.4311 (7)	0.0368 (5)	0.055 (2)

## supplementary materials

---

C2	0.8120 (8)	0.3287 (6)	-0.0384 (5)	0.0528 (19)
C3	0.7418 (9)	0.3499 (7)	-0.1488 (5)	0.0595 (19)
C4	0.6545 (9)	0.4739 (7)	-0.1875 (5)	0.0550 (19)
C5	0.6420 (9)	0.5744 (7)	-0.1208 (5)	0.059 (2)
C6	0.7184 (9)	0.5558 (7)	-0.0071 (5)	0.058 (2)
C7	0.7125 (10)	0.6584 (8)	0.0673 (6)	0.067 (3)
C8	0.7919 (11)	0.6338 (9)	0.1768 (6)	0.075 (3)
C9	0.8687 (11)	0.5055 (9)	0.2115 (6)	0.075 (3)
H3	0.75210	0.28330	-0.19700	0.0710*
H5	0.58330	0.65570	-0.14950	0.0710*
H7	0.65560	0.74140	0.04220	0.0800*
H8	0.79470	0.70100	0.22730	0.0900*
H9	0.91680	0.48940	0.28620	0.0900*

### Atomic displacement parameters ( $\text{\AA}^2$ )

	$U^{11}$	$U^{22}$	$U^{33}$	$U^{12}$	$U^{13}$	$U^{23}$
Br1	0.0902 (6)	0.0440 (5)	0.0739 (5)	0.0092 (4)	0.0106 (4)	0.0044 (3)
Br2	0.1024 (7)	0.0722 (7)	0.0649 (5)	0.0056 (5)	0.0146 (4)	0.0115 (4)
N1	0.065 (3)	0.056 (4)	0.068 (3)	-0.007 (3)	0.018 (2)	-0.005 (3)
C1	0.047 (3)	0.040 (4)	0.074 (4)	-0.003 (3)	0.014 (3)	-0.004 (3)
C2	0.052 (3)	0.033 (4)	0.070 (3)	0.001 (3)	0.016 (3)	0.005 (3)
C3	0.057 (3)	0.049 (4)	0.066 (3)	-0.001 (3)	0.012 (3)	-0.001 (3)
C4	0.056 (3)	0.046 (4)	0.061 (3)	-0.001 (3)	0.017 (3)	0.009 (3)
C5	0.055 (3)	0.043 (4)	0.076 (4)	0.004 (3)	0.019 (3)	0.002 (3)
C6	0.050 (3)	0.047 (4)	0.078 (4)	0.001 (3)	0.024 (3)	-0.004 (3)
C7	0.067 (4)	0.052 (5)	0.084 (4)	0.005 (3)	0.030 (3)	-0.007 (4)
C8	0.079 (5)	0.068 (6)	0.084 (5)	-0.004 (4)	0.036 (4)	-0.013 (4)
C9	0.077 (5)	0.078 (6)	0.070 (4)	-0.016 (4)	0.025 (3)	-0.015 (4)

### Geometric parameters ( $\text{\AA}$ , $^\circ$ )

Br1—C2	1.877 (6)	C5—C6	1.407 (9)
Br2—C4	1.909 (6)	C6—C7	1.414 (10)
N1—C1	1.358 (8)	C7—C8	1.368 (10)
N1—C9	1.332 (10)	C8—C9	1.401 (12)
C1—C2	1.425 (9)	C3—H3	0.9300
C1—C6	1.414 (10)	C5—H5	0.9300
C2—C3	1.370 (9)	C7—H7	0.9300
C3—C4	1.398 (10)	C8—H8	0.9300
C4—C5	1.343 (9)	C9—H9	0.9300
Br1...Br1 <sup>i</sup>	3.4443 (13)		
C1—N1—C9	116.1 (6)	C5—C6—C7	122.2 (6)
N1—C1—C2	118.9 (6)	C6—C7—C8	119.0 (7)
N1—C1—C6	123.8 (6)	C7—C8—C9	118.8 (7)
C2—C1—C6	117.3 (6)	N1—C9—C8	124.8 (7)
Br1—C2—C1	119.4 (5)	C2—C3—H3	121.00
Br1—C2—C3	119.0 (5)	C4—C3—H3	121.00

C1—C2—C3	121.6 (6)	C4—C5—H5	120.00
C2—C3—C4	118.6 (6)	C6—C5—H5	120.00
Br2—C4—C3	117.5 (5)	C6—C7—H7	120.00
Br2—C4—C5	119.9 (5)	C8—C7—H7	120.00
C3—C4—C5	122.7 (6)	C7—C8—H8	121.00
C4—C5—C6	119.5 (6)	C9—C8—H8	121.00
C1—C6—C5	120.3 (6)	N1—C9—H9	118.00
C1—C6—C7	117.5 (6)	C8—C9—H9	118.00
C9—N1—C1—C2	178.9 (6)	C1—C2—C3—C4	-2.1 (10)
C9—N1—C1—C6	-0.3 (10)	C2—C3—C4—C5	2.1 (11)
C1—N1—C9—C8	-1.3 (12)	C2—C3—C4—Br2	-176.9 (5)
N1—C1—C2—Br1	-2.1 (8)	Br2—C4—C5—C6	178.7 (5)
N1—C1—C2—C3	-179.0 (6)	C3—C4—C5—C6	-0.3 (11)
C6—C1—C2—C3	0.3 (9)	C4—C5—C6—C7	179.0 (7)
N1—C1—C6—C5	-179.2 (6)	C4—C5—C6—C1	-1.6 (10)
C6—C1—C2—Br1	177.2 (5)	C1—C6—C7—C8	1.4 (11)
C2—C1—C6—C5	1.6 (10)	C5—C6—C7—C8	-179.2 (7)
C2—C1—C6—C7	-179.0 (6)	C6—C7—C8—C9	-2.8 (12)
N1—C1—C6—C7	0.2 (10)	C7—C8—C9—N1	2.9 (13)
Br1—C2—C3—C4	-179.0 (5)		

Symmetry codes: (i)  $-x+2, -y, -z$ .



Fig. 1




Fig. 2

